2020
Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy
Duek O, Pietrzak RH, Petrakis I, Hoff R, Harpaz-Rotem I. Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy. Journal Of Psychiatric Research 2020, 132: 167-173. PMID: 33126010, DOI: 10.1016/j.jpsychires.2020.10.005.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderRisk factorsEarly discontinuationMedication discontinuationPsychotropic medicationsPoor medication adherenceSimilar risk factorsStrong risk factorDeterminants of discontinuationKey risk factorsRole of psychotherapySingle medicationMedication adherenceMedication treatmentPsychiatric comorbidityAntipsychotic medicationPatient educationDiscontinuationOlder veteransMedicationsAdjunctive psychotherapyYounger veteransEarly interventionU.S. veteransVA treatment
2009
Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. Psychiatric Quarterly 2009, 80: 241-249. PMID: 19768543, DOI: 10.1007/s11126-009-9111-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsInjectable risperidoneLong-Acting Injectable RisperidoneDuration of pharmacotherapyOral conventional antipsychoticsHalf of patientsMultivariable logistic regressionTreatment of schizophreniaDuration of treatmentProportional hazards modelOral antipsychoticsTreatment discontinuationOral medicationsReal-world practiceConventional antipsychoticsPatient characteristicsMedication adherenceAntipsychotic medicationVA patientsHazards modelAntipsychoticsMedicationsPatientsLogistic regressionRisperidone